1World Health Organization. Global Information System on Alcohol and Health. WHO, 2015.
2Bosetti, C, Levi, F, Lucchini, F, Zatonski, WA, Negri, E, La, VC. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827–39.
3Tilg, H, Day, CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 24–34.
4Addolorato, G, Mirijello, A, Leggio, L, Ferrulli, A, Landolfi, R. Management of alcohol dependence in patients with liver disease. CNS Drugs 2013; 27: 287–99.
5Colombo, G, Addolorato, G, Agabio, R, Carai, MA, Pibiri, F, Serra, S, et al. Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004; 6: 403–14.
6Maccioni, P, Colombo, G. Role of the GABA(B) receptor in alcohol-seeking and drinking behavior. Alcohol 2009; 43: 555–8.
7Addolorato, G, Leggio, L, Ferrulli, A, Cardone, S, Vonghia, L, Mirijello, A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370: 1915–22.
8Chaignot, C, Weill, A, Ricordeau, P, Alla, F. Use in france of baclofen for alcohol dependence from 2007 to 2013: cohort study based on the databases SNIIRAM and PMSI. Therapie 2015; 70: 443–53.
9Reynaud, M, Aubin, HJ, Trinquet, F, Zakine, B, Dano, C, Dematteis, M, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol 2017; 52: 439–46.
10Ponizovsky, AM, Rosca, P, Aronovich, E, Weizman, A, Grinshpoon, A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abuse Treat 2015; 52: 24–30.
11Addolorato, G, Caputo, F, Capristo, E, Domenicali, M, Bernardi, M, Janiri, L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol Alcohol 2002; 37: 504–8.
12Morley, KC, Baillie, A, Leung, S, Addolorato, G, Leggio, L, Haber, PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol 2014; 49: 654–60.
13Beraha, EM, Salemink, E, Goudriaan, AE, Bakker, A, de Jong, D, Smits, N, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol 2016; 26: 1950–9.
14Muller, CA, Geisel, O, Pelz, P, Higl, V, Kruger, J, Stickel, A, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2015; 25: 1167–77.
15Morley, KC, Leung, S, Baillie, A, Haber, PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemp Clin Trials 2013; 36: 348–55.
16World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
17Sullivan, JT, Sykora, K, Schneiderman, J, Naranjo, CA, Sellers, EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353–7.
18Teesson, M, Sannibale, C, Reid, SC, Proudfoot, H, Gournay, K, Haber, P. Manual for Compliance Therapy in Alcohol Pharmacotherapy. NDARC Technical Report 157. NDARC, 2003.
19Sobell, LC, Maisto, SA, Sobell, MB, Cooper, A. Reliability of alcohol abusers’ self-reports of drinking behavior. Behav Res Ther 1979; 17: 157–60.
20Morley, KC, Teesson, M, Reid, SC, Sannibale, C, Thomson, C, Phung, N, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101: 1451–62.
21Morley, KC, Baillie, A, Leung, S, Sannibale, C, Teesson, M, Haber, PS. Is specialized integrated treatment for comorbid anxiety, depression and alcohol dependence better than treatment as usual in a public hospital setting? Alcohol Alcohol 2016; 51: 402–9.
22Child, CG, Turcotte, JG. Surgery and portal hypertension. In The Liver and Portal Hypertension (ed Child, CG): 50–64. Saunders, 1964.
23Maddrey, WC, Boitnott, JK, Bedine, MS, Weber, FL, Mezey, E, White, RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75 (2): 193–9.
24Kamath, PS, Kim, WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45 (3): 797–805.
25Skinner, HA, Allen, BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 1982; 91: 199–209.
26Flannery, B, Volpicelli, J, Pettinati, H. Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23: 1289–95.
27Lovibond, PF, Lovibond, SH. Manual for the Depression Anxiety Stress Scales. Psychology Foundation of Australia, 1995.
28Bastien, CH, Vallieres, A, Morin, CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med 2001; 2: 297–307.
29Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59 (suppl 20): 22–33.
30Schulz, KF, Altman, DG, Moher, D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Br Med J 2010; 340: c332.
31Hallgren, KA, Witkiewitz, K. Missing data in alcohol clinical trials: a comparison of methods. Alcohol Clin Exp Res 2013; 37: 2152–60.
32Gupta, M, Verma, P, Rastogi, R, Arora, S, Elwadhi, D. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. Am J Drug Alcohol Abuse 2017; 43: 324–31.
33Garbutt, JC, Kampov-Polevoy, AB, Gallop, R, Kalkajuhl, L, Flannery, BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2012; 34: 1849–57.
34Hauser, P, Fuller, B, Ho, SB, Thuras, P, Kern, S, Dieperink, E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction 2017; 112: 1173–83.
35Behar, KL, Rothman, DL, Petersen, KF, Hooten, M, Delaney, R, Petroff, OA, et al. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry 1999; 156: 952–4.
36Leggio, L, Lee, MR. Treatment of Alcohol Use Disorder in Patients with Alcoholic Liver Disease. Am J Med 2017; 130: 124–34.
37Owens, L, Thompson, A, Rose, A, Gilmore, I, Pirmohamed, M, Richardson, P. A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic. Alcohol 2017; 62: 11–5.
38Yamini, D, Lee, SH, Avanesyan, A, Walter, M, Runyon, B. Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis. Alcohol Alcohol 2014; 49: 453–6.
39Chick, J, Nutt, DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol 2012; 26: 205–12.
40Farokhnia, M, Schwandt, ML, Lee, MR, Bollinger, JW, Farinelli, LA, Amodio, JP, et al. Biobehavioral effects of baclofen in anxious alcohol-dependent individuals: a randomized, double-blind, placebo-controlled, laboratory study. Transl Psychiatry 2017; 7: e1108.
41Leggio, L, Zywiak, WH, McGeary, JE, Edwards, S, Fricchione, SR, Shoaff, JR, et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacol Biochem Behav 2013; 103: 784–91.
42Leung, NY, Whyte, IM, Isbister, GK. Baclofen overdose: defining the spectrum of toxicity. Emerg Med Australas 2006; 18: 77–82.
43Rolland, B, Labreuche, J, Duhamel, A, Deheul, S, Gautier, S, Auffret, M, et al. Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 2015; 25: 1631–6.
44Dore, GM, Lo, K, Juckes, L, Bezyan, S, Latt, N. Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series. Alcohol Alcohol 2011; 46: 714–20.